

## Supplemental tables

**Supplemental table 1:** combination of cardiovascular therapies.

ATC code	Designation	Number of active substances
C10BA	HMG CoA reductase inhibitors in combination with other lipid modifying agents	2
C10BX	HMG CoA reductase inhibitors, other combinations	
	C10BX01;C10BX02;C10BX03;C10BX05;C10BX08;C10BX09;C10BX10	2
	C10BX04;C10BX06;C10BX07;C10BX11;C10BX12	3
C02L	ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION	2
C03E	DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION	2
C07B	BETA BLOCKING AGENTS AND THIAZIDES	2
C07C	BETA BLOCKING AGENTS AND OTHER DIURETICS	2
C07D	BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS	3
C07E	BETA BLOCKING AGENTS AND VASODILATORS	2
C07F	BETA BLOCKING AGENTS, OTHER COMBINATIONS	2
C08G	CALCIUM CHANNEL BLOCKERS AND DIURETICS	2
C09BA	ACE inhibitors and diuretics	2
C09BB	ACE inhibitors and calcium channel blockers	2
C09BX01	perindopril, amlodipine and indapamide	3
C09BX02	perindopril and bisoprolol	2
C09DA	Angiotensin II antagonists and diuretics	2
C09DB	Angiotensin II antagonists and calcium channel blockers	2
C09DX01	valsartan, amlodipine and hydrochlorothiazide	3
C09DX02	valsartan and aliskiren	2
C09DX03	olmesartan medoxomil, amlodipine and hydrochlorothiazide	3
C09DX04	valsartan and sacubitril	2

**Supplemental table 2:** comparison between included and excluded participants, Colaus study, Lausanne, Switzerland.

	<b>Included</b>	<b>Excluded</b>	<b>p-value</b>
Sample size	880	452	
Men (%)	441 (50.1)	268 (59.3)	0.001
Age (years)	59.9 ± 9.1	61.7 ± 9.6	<0.001
Born in Switzerland (%)	631 (71.7)	283 (62.6)	0.001
Smoking status (%)			0.010
Never	336 (38.2)	148 (32.9)	
Former	351 (39.9)	170 (37.8)	
Current	193 (21.9)	132 (29.3)	
Alcohol consumption (%)	644 (73.2)	309 (68.4)	0.065

Results are expressed as number of participants and (%) or as average ± standard deviation.

Comparisons performed using chi-square for categorical variables and student's t-test for continuous variables.